Are you attending #DTxEast2023 in #Boston next month? Join our CEO Frank Karbe and Chief Commercial Officer Diane Gomez-Thinnes there for the #DTx industry's premier event.

Diabetes Prevalence Continues To Rise – Better Therapeutics' Digital Treatment Could Help Change This Trajectory $BTTX $LLY $NVO benzinga.com/general/biotec… via Benzinga

Better Therapeutics Completes Enrollment in Real-World Evidence Program Evaluating Long-term Effectiveness of AspyreRx in Type 2 Diabetes - businesswire.com/news/home/2023…

As we witness the transformative impact of digital therapeutics on conditions like type 2 diabetes, MASLD and MASH, we envision a future where PDTs not only serve as first-line treatments, but also complement pharmacotherapy, empowering patients to... businesswire.com/news/home/2023…

Better Therapeutics Announces New Data Highlighting Concurrent Use of AspyreRx and GLP-1 Receptor Agonists to Treat Type 2 Diabetes - businesswire.com/news/home/2023…

Better Therapeutics Announces Launch of AspyreRx to Treat Adults with Type 2 Diabetes - businesswire.com/news/home/2023…

Behavior change can be powerful #medicine. Today, adults with T2D have a new treatment option that requires a prescription - and it’s not a drug. AspyreRx is now live in app stores and healthcare providers across the U.S. can start prescribing today. aspyrerx.com

#news We are days away from the American College of Lifestyle Medicine's #LM2023 meeting in Denver. #AspyreRx will be on showcase and we are excited to share it with the #lifestylemedicine and #healthcare community. Read more 👉 lnkd.in/gRr6EV_Q

#AspyreRx is on showcase at #LM2023! The team are thrilled to be here in Denver with the #lifestylemedicine community to drive the transformation of #healthcare. Visit us at the booth to learn more. American College of Lifestyle Medicine

Wrapping up at #LM2023! It's been inspiring connecting with the #lifestylemedicine community, sharing insights, and exploring innovative approaches. The support & feedback for #AspyreRx has been incredible. Together, we believe behavior change can be powerful medicine.

On #WorldDiabetesDay we are thrilled to share we have been awarded the 🏆 2023 Technology Innovation Leadership Award for #AspyreRx, a digital behavioral treatment for people living with #type2diabetes. Read the full Frost & Sullivan report 👉 lnkd.in/dNBb-U25

Despite advances in #pharmacotherapy, there remains a pressing need to revolutionize the approach to #diabetes treatment. We are utilizing #tech on our mission to advance human health through the power of behavior change. benzinga.com/general/biotec…

Discover a new way to treat type 2 diabetes – and it’s not a drug. Join us for our upcoming webinar to learn how AspyreRx™ can help your patients make and maintain positive behavior changes to improve their type 2 diabetes. Register at bit.ly/410B9A8.

🗓️ Join us on Thursday at 1pm EST to discover how behavior change can be powerful medicine. Register here adces.org/events/virtual…

Are you a #diabetes educator? Interesting in learning how to help your patients make and sustain behavior change? Join ADCES for a product overview webinar to discover how AspyreRx can help. Register now at bit.ly/410B9A8.

The versatility of our therapeutic approach across a broad spectrum of cardiometabolic conditions is an exciting and unique aspect of our platform. Furthermore, the digital nature of our products allows for potential expansion in a fraction of the time... businesswire.com/news/home/2024…

#news In a step towards securing broad coverage for AspyreRx, we announced today a rebate agreement with a large PBM in the US. businesswire.com/news/home/2024…

#news FDA grants Breakthrough Device Designation for our novel CBT platform targeting patients with advanced liver disease. Read more 👉 businesswire.com/news/home/2024…

Why do many patients with #T2D struggle with making lifestyle changes that stick? Join Better Therapeutics to learn more about the science behind cognitive behavioral therapy and see how AspyreRx can help your patients succeed. Learn more 👉 bit.ly/3wwQAoR

#breakingnews An innovative partnership with ACLM is set to expand access to AspyreRx to patients in underserved communities disproportionately affected by #T2D businesswire.com/news/home/2024…